This drug could be used to where other late stage drugs have not been helpful therapies and the drug does extend overall survival for patients. BD
MONDAY, Nov. 15 (HealthDay News) -- Halaven (eribulin mesylate) has been approved by the U.S. Food and Drug Administration to treat metastatic (spreading) breast cancer among people who have had at least two prior chemotherapy treatments for late-stage disease.
In a news release published Monday, the agency said breast cancer is the second-leading cancer cause of death of among women, citing statistics from the National Cancer Institute. Some 207,090 women are expected to be diagnosed with breast cancer this year, resulting in 39,840 deaths, the FDA said.
Other FDA-approved therapies used to treat late-stage, refractory breast cancer include Xeloda (capecitabine) for patients with breast cancer resistant to paclitaxel and anthracycline-containing chemotherapy; Ixempra (ixabepilone) for patients with late-stage disease after failure of an anthracycline, taxane and Xeloda; and Ixempra plus Xeloda for patients with late-stage disease after failure of anthracycline- and taxane-based chemotherapy.
0 comments :
Post a Comment